 Connection
Matthew Greenhawt to Canada
This is a "connection" page, showing publications Matthew Greenhawt has written about Canada.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.097 |
|
|
|
-
Shaker M, Chan ES, Protudjer JLP, Soller L, Abrams EM, Greenhawt M. The Cost-Effectiveness of Preschool Peanut Oral Immunotherapy in the Real-World Setting. J Allergy Clin Immunol Pract. 2021 07; 9(7):2876-2884.e4.
Score: 0.172
-
Shaker M, Abrams EM, Greenhawt M. A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies. J Allergy Clin Immunol Pract. 2021 07; 9(7):2658-2668.e3.
Score: 0.171
-
Fleischer DM, Chan ES, Venter C, Spergel JM, Abrams EM, Stukus D, Groetch M, Shaker M, Greenhawt M. A Consensus Approach to the Primary Prevention of Food Allergy Through Nutrition: Guidance from the American Academy of Allergy, Asthma, and Immunology; American College of Allergy, Asthma, and Immunology; and the Canadian Society for Allergy and Clinical Immunology. J Allergy Clin Immunol Pract. 2021 01; 9(1):22-43.e4.
Score: 0.168
-
Abrams EM, Greenhawt M. The role of peanut-free school policies in the protection of children with peanut allergy. J Public Health Policy. 2020 Jun; 41(2):206-213.
Score: 0.163
-
Shaker M, Stukus D, Chan ES, Fleischer DM, Spergel JM, Greenhawt M. "To screen or not to screen": Comparing the health and economic benefits of early peanut introduction strategies in five countries. Allergy. 2018 Aug; 73(8):1707-1714.
Score: 0.141
-
Greenhawt MJ, Vickery BP. Allergist-reported trends in the practice of food allergen oral immunotherapy. J Allergy Clin Immunol Pract. 2015 Jan-Feb; 3(1):33-8.
Score: 0.110
-
Alqurashi W, Shaker M, Wells GA, Collins GS, Greenhawt M, Curran JA, Zemek R, Schuh S, Ellis A, Gerdts J, Kreviazuk C, Dixon A, Eltorki M, Freedman SB, Gravel J, Poonai N, Worm M, Plint AC. Canadian Anaphylaxis Network-Predicting Recurrence after Emergency Presentation for Allergic REaction (CAN-PREPARE): a prospective, cohort study protocol. BMJ Open. 2022 10 31; 12(10):e061976.
Score: 0.048
-
Abrams EM, Greenhawt M, Shaker M, Kosowan L, Singer AG. Primary care provider-reported prevalence of vaccine and polyethylene glycol allergy in Canada. Ann Allergy Asthma Immunol. 2021 10; 127(4):446-450.e1.
Score: 0.043
-
Wasserman RL, Factor J, Windom HH, Abrams EM, Begin P, Chan ES, Greenhawt M, Hare N, Mack DP, Mansfield L, Ben-Shoshan M, Stukus DR, Leek TV, Shaker M. An Approach to the Office-Based Practice of Food Oral Immunotherapy. J Allergy Clin Immunol Pract. 2021 05; 9(5):1826-1838.e8.
Score: 0.043
-
Abrams EM, Soller L, Singer AG, Fleischer DM, Greenhawt M, Chan ES. Comparison of practice patterns among Canadian allergists before and after NIAID guideline recommendations. J Allergy Clin Immunol Pract. 2019 Nov - Dec; 7(8):2901-2903.e3.
Score: 0.038
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|